MedTrace Logo

A Study Of Mircera In Patients With Kidney Disease Who Are Not On Dialysis

NCT02490514 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 153

Last updated 2015-08-18

No results posted yet for this study

Summary

This open-label, non-randomized, retrospective-prospective, non-interventional study will evaluate the efficacy and safety of Mircera in patients with stage III-IV chronic kidney disease (CKD) not on dialysis. Patients will receive open-label treatment with Mircera for 12 months at a dose to be determined by the investigator.

Conditions

  • Renal Tubular Acidosis, Distal, With Hemolytic Anemia

Interventions

OTHER

No intervention

No intervention was administered in this study.

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2012-02-29
Completion
2012-02-29

Countries

  • Serbia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02490514 on ClinicalTrials.gov